Latest Rigel Pharmaceuticals Inc. Stories
SOUTH SAN FRANCISCO, Calif., Dec. 7, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief operating officer, is scheduled to present a company overview at the Oppenheimer 22nd Annual Healthcare Conference in New York City on Wednesday, December 14th at 1:00 p.m. ET. (Logo: <font size="2" face="Arial">http://photos.prnewswire.com/prnh/20030226/RIGLLOGO</font>) To access the live audio...
SOUTH SAN FRANCISCO, Calif., Nov. 3, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, chairman and chief executive officer, and Ryan Maynard, executive vice president and chief financial offer of Rigel, will participate at two investor conferences in November. Details of the events are as follows: (Logo: http://photos.prnewswire.com/prnh/20030226/RIGLLOGO) 2011 Credit Suisse Annual Health Care ConferenceDate: Thursday, November 10 at...
SOUTH SAN FRANCISCO, Calif., Nov. 1, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the third quarter and nine months ended September 30, 2011. For the third quarter of 2011, Rigel reported a net loss of $17.9 million, or $0.25 per basic and diluted share, compared to a net income of $50.4 million, or $0.97 and $0.96 per basic and diluted share, respectively, in the same period of 2010. Basic weighted average shares outstanding for the...
SOUTH SAN FRANCISCO, Calif., Oct. 6, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will provide a live webcast of its upcoming Investor/Analyst Day on Thursday, October 13, 2011 at 10:00am EDT. Members of Rigel's senior management team will provide an overview of the company's product pipeline, as well as discuss the Phase 2 strategy for R343, their inhaled syk inhibitor for asthma. To view the multimedia assets associated with this release,...
SOUTH SAN FRANCISCO, Calif., Aug. 25, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, chairman and chief executive officer, and Ryan Maynard, executive vice president and chief financial officer of Rigel, will present at two separate investor conferences in September. Details of the events are as follows: Stifel Nicolaus Healthcare Conference 2011 Date: Thursday, September 8th at 10:20 a.m. ET Location: Boston, MA...
SOUTH SAN FRANCISCO, Calif., Aug. 2, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the second quarter and six months ended June 30, 2011. For the second quarter of 2011, Rigel reported a net loss of $21.5 million, or $0.37 per basic and diluted share, compared to a net income of $27.0 million, or $0.52 and $0.51 per basic and diluted share, respectively, in the same period of 2010. Basic weighted average shares outstanding for the...
SOUTH SAN FRANCISCO, Calif., June 16, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul R. Rodriguez, the company's president and chief operating officer, is scheduled to present a company overview at the Wells Fargo Securities 2011 Healthcare Conference in Boston, MA on Thursday, June 23rd at 9:30 a.m. ET. To access the live audio webcast of the company presentation or the subsequent archived recording, log on to www.rigel.com. Please connect to...
SOUTH SAN FRANCISCO, June 3, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the Jefferies 2011 Global Healthcare Conference in New York City on Wednesday, June 8th at 2:30 pm ET. The presentation will be webcast live and can be accessed at www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live...
SOUTH SAN FRANCISCO, Calif., May 26, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced the pricing of its previously announced underwritten public offering of 16,300,000 shares of its common stock, offered at a price of $8.00 per share to the public. The gross proceeds to Rigel from this offering are expected to be approximately $130,400,000, before deducting underwriting discounts and commissions, and other estimated offering expenses payable by Rigel. All...
SOUTH SAN FRANCISCO, Calif., May 25, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares in the offering are to be sold by Rigel. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Jefferies & Company,...
